View this email in your browser
Newsletter volume 8. October 2022
Dear <<First Name>>

Medicines Development for Global Health is pleased to provide updates on our latest activities. Your feedback and suggestions for future newsletters are welcomed, and please feel free to forward our news to your colleagues who may be interested in our company's mission and work.
2021 Annual Report published
Medicines Development for Global Health has just released its 2021 Annual Report. We invite you to read more about what we’ve been working on this past year and see what our plans are for the future. Download your copy here:
American Society of Tropical Medicine and Hygiene Annual Meeting
Medicines Development for Global Health will attend the 2022 American Society of Tropical Medicine and Hygiene meeting, being held from October 30 to November 3 in Seattle, Washington. In addition to presentations on moxidectin clinical trial data, Medicines Development for Global Health will also have a booth in the exhibitor area (booth 220). If you are coming to the meeting, please stop by to learn more about updates to our research pipeline, and our upcoming pilot field studies.

Find out more here:
Medicines Development for Global Health Signs the Kigali Declaration
Mark Sullivan, AO, Founder and Managing Director of Medicines Development for Global Health, participates in a panel discussion at the Kigali Summit. (Photo credit: Uniting to Combat Neglected Tropical Diseases)
Concurrent to the 26th Commonwealth Heads of Government Meeting in Rwanda, the Kigali Summit on Malaria and Neglected Tropical Diseases brought together presidents, prime ministers, royalty, NGOs, industry, affected community and business leaders, and philanthropists to sign a new declaration to update the commitments made in the 2012 London Declaration. Specifically, this year’s Summit was a forum to renew high-level commitments to end malaria and neglected tropical diseases and provide an opportunity to secure both political support as well as investment in integrating disease programs. The aim of the Kigali Declaration is to mobilise political will and secure the financial commitments needed to achieve the Sustainable Development Goal 3 (SDG3) and deliver on the targets set out by the World Health Organization’s Neglected Tropical Disease Roadmap (2021-2030).

Medicines Development for Global Health’s Founder and Managing Director, Mark Sullivan AO, participated in one of the afternoon panel discussion sessions on access to innovation in the global public health community.
“Such impressive progress has been made towards the goal of eliminating neglected tropical diseases, with over half a billion people no longer requiring treatments for these diseases. Yet there remain over 1.7 billion people who continue to suffer from at least one neglected tropical disease. The continued burden of disease highlights the need to increase our efforts. By signing the Kigali Declaration, we wanted to make public our commitment to contributing what we can to achieve the goal of removing these diseases from the lives of so many people.”
Mark Sullivan AO,
Managing Director, Medicines Development for Global Health.
Job Opportunities
We are currently seeking qualified candidates for several important roles at Medicines Development for Global Health. Please click the links to the job descriptions below. If any of these describe you, or you know someone who may be interested, please get in touch.
Please stay in touch with us.
MDGH Website
Copyright © 2022, Medicines Development for Global Health. All rights reserved.

Our mailing address is:
Level 1 - 18 Kavanagh Street,
Southbank VIC 3006 Australia

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.